IMUN: AI 评分 44/100 — AI 分析 (4月 2026)

Immune Therapeutics, Inc. is a healthcare company that currently does not have significant operations. Formerly known as TNI BioTech, Inc., the company changed its name in October 2014 and is headquartered in Orlando, Florida.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Immune Therapeutics, Inc., formerly TNI BioTech, operates within the biotechnology sector but currently lacks significant operational activity. The company, headquartered in Orlando, Florida, focuses on the healthcare industry, though its current business activities are minimal, presenting a speculative investment profile.

IMUN是做什么的？

Immune Therapeutics, Inc., originally established as TNI BioTech, underwent a name change in October 2014, signaling a strategic shift that has yet to materialize into substantial operational activities. Headquartered in Orlando, Florida, the company exists within the biotechnology sector, a field known for its high-risk, high-reward potential. However, Immune Therapeutics, Inc. presently does not have significant operations, indicating a company in a developmental or transitional phase. The company's history suggests a potential pivot towards immune-related therapies, aligning with the biotechnology industry's focus on innovative healthcare solutions. Despite this, the absence of current operations raises questions about the company's strategic direction and future prospects. The company's evolution from TNI BioTech to Immune Therapeutics suggests an intention to capitalize on the growing interest in immunotherapy and related fields, but the lack of tangible business activities makes it difficult to assess its competitive positioning and long-term viability. The company's future hinges on its ability to develop and commercialize viable products or services within the biotechnology sector.

IMUN的投资论点是什么？

Investing in Immune Therapeutics, Inc. (IMUN) presents a highly speculative opportunity due to the company's current lack of significant operations. With a market capitalization of $0.01 billion and a negative price-to-earnings ratio, traditional valuation metrics offer limited insight. The company's beta of 0.26 suggests lower volatility compared to the market. Potential catalysts include the announcement of new strategic initiatives or the acquisition of assets that could revitalize the company's operations. However, the primary risk lies in the uncertainty surrounding the company's future direction and its ability to generate revenue. Investors should carefully consider the speculative nature of this investment and the potential for significant losses.

IMUN在哪个行业运营？

Immune Therapeutics, Inc. operates within the biotechnology sector, an industry characterized by intense research and development, high regulatory hurdles, and significant growth potential. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by advancements in genomics, personalized medicine, and immunotherapy. However, the industry is also highly competitive, with numerous companies vying for market share. Immune Therapeutics, Inc.'s lack of significant operations places it at a disadvantage compared to established players like BNOEF (BioNtech SE), CRBKF (CARB-X), FWPAY (Forward Pharma A/S), HBCNF (Hope Biosciences), and IPCIF (InPro Biotechnology Inc.), which have active research programs and commercialized products.

Biotechnology

Healthcare

IMUN有哪些增长机遇？

Strategic Acquisition: Immune Therapeutics could pursue strategic acquisitions of promising biotechnology assets or companies. This would provide an immediate boost to its operational capabilities and pipeline. The market for biotech acquisitions is robust, with numerous opportunities to acquire undervalued assets. Timeline: Within the next 1-2 years.
Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions could provide Immune Therapeutics with access to funding, expertise, and resources. Collaborative agreements are common in the biotechnology industry and can accelerate the development and commercialization of new therapies. Timeline: Ongoing.
Focus on Niche Therapeutic Areas: Immune Therapeutics could focus on developing therapies for niche therapeutic areas with unmet medical needs. This would allow the company to differentiate itself from larger competitors and potentially achieve faster regulatory approval. The market for orphan drugs and rare disease therapies is growing rapidly. Timeline: Within the next 3-5 years.
Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems could enhance the efficacy and safety of existing therapies. This would create a competitive advantage and potentially attract partnerships with pharmaceutical companies seeking to improve their product portfolios. The market for drug delivery technologies is expanding. Timeline: Within the next 3-5 years.
Capitalizing on Immunotherapy Advancements: Given its name, Immune Therapeutics could explore opportunities in the rapidly expanding field of immunotherapy. This could involve developing novel immunotherapies for cancer or other diseases, or partnering with companies that have promising immunotherapy candidates. The immunotherapy market is experiencing significant growth. Timeline: Ongoing.

Market capitalization of $0.01 billion, indicating a micro-cap company.
Negative P/E ratio due to the absence of significant operations and earnings.
Beta of 0.26, suggesting lower volatility compared to the broader market.
No dividend yield, consistent with companies in a developmental or transitional phase.
Change of name from TNI BioTech to Immune Therapeutics, Inc. in October 2014, signaling a strategic shift.

IMUN提供哪些产品和服务？

Formerly known as TNI BioTech, Inc.
Changed its name to Immune Therapeutics, Inc. in October 2014.
Headquartered in Orlando, Florida.
Operates within the healthcare sector.
Focuses on the biotechnology industry.
Currently does not have significant operations.

IMUN如何赚钱？

Currently, the business model is not clearly defined due to the lack of significant operations.
Potentially focused on developing or acquiring immune-related therapies.
Future revenue generation dependent on strategic initiatives and partnerships.

Not applicable due to the lack of significant operations.
Potential future customers could include patients, healthcare providers, and pharmaceutical companies.
Customer base dependent on the development and commercialization of specific products or services.

Currently, there is no discernible economic moat due to the lack of significant operations.
Potential future moat could be established through intellectual property, strategic partnerships, or unique therapeutic approaches.
Moat development dependent on successful execution of strategic initiatives.

什么因素可能推动IMUN股价上涨？

Upcoming: Announcement of new strategic initiatives or partnerships.
Upcoming: Acquisition of biotechnology assets or companies.
Ongoing: Potential for breakthroughs in immune-related therapies.
Ongoing: Changes in the regulatory landscape for biotechnology companies.
Ongoing: Developments in the broader healthcare sector.

IMUN的主要风险是什么？

Potential: Lack of significant operations may lead to delisting or dissolution.
Potential: Intense competition within the biotechnology sector.
Potential: Regulatory hurdles and clinical trial risks.
Ongoing: Uncertainty surrounding future funding and capital raising.
Ongoing: Dependence on external factors and market conditions.

IMUN的核心优势是什么？

Potential for strategic repositioning within the biotechnology sector.
Name recognition associated with immune-related therapies.
Low beta suggests lower volatility.
Existing corporate structure allows for rapid deployment of new strategies.

IMUN的劣势是什么？

Lack of significant operations.
Unclear strategic direction.
Limited financial resources.
Absence of revenue generation.

IMUN有哪些机遇？

Strategic acquisitions of promising biotechnology assets.
Partnerships with larger pharmaceutical companies.
Focus on niche therapeutic areas with unmet medical needs.
Development of novel drug delivery systems.

IMUN面临哪些威胁？

Intense competition within the biotechnology sector.
Regulatory hurdles and clinical trial risks.
Uncertainty surrounding future funding and capital raising.
Potential for obsolescence of existing technologies.

IMUN的竞争对手是谁？

BioNtech SE — Focuses on mRNA-based therapies and vaccines. — (BNOEF)
CARB-X — A global non-profit accelerating antibacterial innovation. — (CRBKF)
Forward Pharma A/S — Engaged in the development of proprietary formulations of DMF. — (FWPAY)
Hope Biosciences — Focuses on adult stem cell research and therapies. — (HBCNF)
InPro Biotechnology Inc. — Develops and manufactures cell culture media and reagents. — (IPCIF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Noreen M. Griffin
Headquarters: Winter Park, US
Founded: 2010

AI Insight

AI analysis pending for IMUN

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Immune Therapeutics, Inc. do?

Immune Therapeutics, Inc. currently does not have significant operations, but it is positioned within the healthcare sector, specifically the biotechnology industry. Formerly known as TNI BioTech, Inc., the company changed its name in October 2014, suggesting a potential focus on immune-related therapies. However, the absence of current business activities makes it difficult to define its specific products or services. The company's future direction will depend on its ability to develop or acquire viable assets and execute a clear strategic plan.

What do analysts say about IMUN stock?

Due to the company's lack of significant operations and limited financial disclosure, there is currently no analyst coverage for Immune Therapeutics, Inc. (IMUN). Traditional valuation metrics such as price-to-earnings ratio are not applicable, and the company's future prospects are highly uncertain. Investors should conduct their own thorough due diligence and consider the speculative nature of this investment before making any decisions.

What are the main risks for IMUN?

The main risks for Immune Therapeutics, Inc. (IMUN) stem from its lack of significant operations and limited financial disclosure. Investing in OTC Other tier stocks carries inherent risks, including low liquidity, wide bid-ask spreads, and potential for fraud or manipulation. The company's future viability depends on its ability to secure funding, develop or acquire viable assets, and navigate the competitive biotechnology landscape. Investors should be aware of the potential for significant losses.